Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? by 신재일
Contents lists available at ScienceDirect 
Autoimmunity Reviews 
journal homepage: www.elsevier.com/locate/autrev 
Rituximab in adult minimal change disease and focal segmental 
glomerulosclerosis - What is known and what is still unknown? 
Philipp Gaucklera,⁎, Jae Il Shinb,c,d, Federico Albericie,f, Vincent Audardg, Annette Bruchfeldh,ah,  
Martin Buschi, Chee Kay Cheungj,k, Matija Crnogoracl, Elisa Delbarbam, Kathrin Ellern,  
Stanislas Faguero,p, Kresimir Galesicl, Siân Griffinq, Zdenka Hruškovár, Anushya Jeyabalans,  
Alexandre Karrast, Catherine Kingu, Harbir Singh Kohliv, Rutger Maasw, Gert Mayera,  
Sergey Moiseevx, Masahiro Mutoy, Balazs Odlern, Ruth J. Pepperz, Luis F. Quintanaaa,  
Jai Radhakrishnans, Raja Ramachandranv, Alan D. Salamaz, Mårten Segelmarkab, Vladimír Tesařr,  
Jack Wetzelsw, Lisa Willcocksac, Martin Windpesslad,ae, Ladan Zandaf, Reza Zonoziag,  
Andreas Kronbichlera,⁎, for the RITERM study group 
a Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria 
b Department of Pediatrics, Yonsei University College of Medicine, Seoul 03722, Republic of Korea 
c Division of Pediatric Nephrology, Severance Children's Hospital, Seoul 03722, Republic of Korea 
d Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul 03722, Republic of Korea 
e Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy 
f Department of Medical and Surgical Specialities, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy 
g Department of Nephrology and Transplantation, Rare French Disease Centre "Idiopathic Nephrotic syndrome", Henri-Mondor/Albert-Chenevier Hospital Assistance 
Publique-Hôpitaux de Paris, Inserm U955, Team 21, Paris-East University, 94000 Créteil, France 
h Department of Renal Medicine, CLINTEC, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden 
i Department of Internal Medicine III, University Hospital Jena, Friedrich-Schiller-University, Jena, Germany 
j Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom 
k John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom 
l Department of Nephrology and Dialysis, Dubrava University Hospital, Avenija Gojka Suska 6, 10 000 Zagreb, Croatia 
m Department of Nephrology, University of Brescia, Hospital of Montichiari, Brescia, Italy 
n Clinical Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria 
o Département de Néphrologie et Transplantation d'Organes, Centre de Référence des Maladies Rénales Rares, Centre Hospitalier Universitaire de Toulouse, 31000 
Toulouse, France 
p Institut National de la Santé et de la Recherche Médicale, U1048 (Institut des Maladies Cardiovasculaires et Métaboliques-équipe 12), 31000 Toulouse, France 
q Department of Nephrology and Transplantation, University Hospital of Wales, Cardiff, UK 
r Department of Nephrology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic 
s Division of Nephrology, Columbia University Medical Center, NY, New York, USA 
t Service de Néphrologie, Hôpital Européen-Georges Pompidou, Assistance Publique des Hôpitaux de Paris, 75015 Paris, France 
u Centre for Translational Inflammation Research University of Birmingham Research Laboratories, Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham 
B15 2WB, UK 
v Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India 
w Department of Nephrology, Radboud University Medical Center, PO Box 9101, 6500, HB, Nijmegen, Netherlands 
x Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia 
y Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan 
z University College London Department of Renal Medicine, Royal Free Hospital, London, UK 
aa Department of Nephrology and Renal Transplantation, Hospital Clínic, Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud 
(CSUR), Department of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain 
ab Department of Clinical Sciences Lund, University, Skane University Hospital, Nephrology Lund, Lund, Sweden 
ac Department of Renal Medicine, Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK 
ad Department of Internal Medicine IV, Section of Nephrology, Klinikum Wels-Grieskirchen, Wels, Austria 
ae Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, 4040 Linz, Austria 
af Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA 
ag Division of Nephrology, Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital, 101 Merrimac Street, Boston, MA 02114, USA 
ah Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.  
https://doi.org/10.1016/j.autrev.2020.102671 
Received 1 May 2020; Accepted 6 May 2020    
⁎ Corresponding authors. 
E-mail addresses: philipp.gauckler@i-med.ac.at (P. Gauckler), andreas.kronbichler@i-med.ac.at (A. Kronbichler). 
Autoimmunity Reviews 19 (2020) 102671
Available online 15 September 2020
1568-9972/ © 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T




Minimal change disease 
Focal segmental glomerulosclerosis 
Long-term remission 
Infections 
A B S T R A C T   
Primary forms of minimal change disease and focal segmental glomerulosclerosis are rare podocytopathies and 
clinically characterized by nephrotic syndrome. Glucocorticoids are the cornerstone of the initial im-
munosuppressive treatment in these two entities. Especially among adults with minimal change disease or focal 
segmental glomerulosclerosis, relapses, steroid dependence or resistance are common and necessitate re-in-
itiation of steroids and other immunosuppressants. Effective steroid-sparing therapies and introduction of less 
toxic immunosuppressive agents are urgently needed to reduce undesirable side effects, in particular for patients 
whose disease course is complex. Rituximab, a B cell depleting monoclonal antibody, is increasingly used off- 
label in these circumstances, despite a low level of evidence for adult patients. Hence, critical questions con-
cerning drug-safety, long-term efficacy and the optimal regimen for rituximab-treatment remain unanswered. 
Evidence in the form of large, multicenter studies and randomized controlled trials are urgently needed to 
overcome these limitations.   
1. Background 
Nephrotic syndrome (NS) describes a clinical condition with heavy 
proteinuria, hypoalbuminemia, edema, hyperlipidemia and other as-
sociated features such as coagulation disorders and acute kidney injury. 
Minimal change disease (MCD) and primary focal segmental glomer-
ulosclerosis (FSGS) are among the leading causes of primary NS in 
adults. The overall incidence of these glomerulopathies is very low 
(0.6–1.8 per 100,000 adults for MCD and FSGS) [1]. Uncertainty exists 
about the pathogenesis and optimal treatment strategies for MCD and 
FSGS, especially among adult patients [2]. In this review, we focus on 
the potential role of rituximab in adult MCD and primary FSGS. 
Especially in childhood, the umbrella term idiopathic NS is still 
often used collectively for primary MCD and FSGS. MCD is the most 
common cause of idiopathic NS in childhood, accounting for up to 90% 
of cases. Because of its favorable course and high response rates to oral 
corticosteroids, renal biopsy is not performed routinely and the disease 
is thus termed ‘steroid-sensitive nephrotic syndrome’ in pediatric pa-
tients [3]. Prevalence and steroid responsiveness however decrease 
with age. Consequently, MCD accounts for only 10%–15% of adult 
patients with idiopathic NS and is associated with a longer time to re-
mission under corticosteroid treatment and a higher risk of acute 
kidney injury [3,4]. Nonetheless, overall long-term prognosis for adults 
with MCD is still excellent with remission rates of 75%–90% and a low 
risk for end stage kidney disease (ESKD) < 5% [5]. The diagnosis MCD 
implies the absence of glomerular lesions on light microscopy (LM). 
Immunofluorescence for deposits is usually negative and extensive 
podocyte foot process effacement is detected by electron microscopy 
(EM) [3]. 
Primary FSGS is thought to be an immune-mediated podocytopathy 
accompanied by a characteristic focal pattern of glomerulosclerosis 
with five different histologic variants on LM. Similar histological find-
ings on LM are observed in patients with secondary forms of FSGS 
which are a sign of adaptive glomerular changes due to excessive ne-
phron workload and hyperfiltration [6–8]. In addition to adaptive 
glomerular changes, the term secondary FSGS encompasses various 
other conditions such as genetic, virus-associated or drug-induced 
forms, that often are difficult to distinguish from true idiopathic/pri-
mary FSGS and should be managed conservatively, aiming to control 
blood pressure and proteinuria [6,9]. Hence, establishing the correct 
diagnosis is crucial for the management of patients and an important 
hurdle in the recruitment of respective clinical trials. Interpretation of 
FSGS-studies is complex as mixed cohorts with primary and secondary 
disease forms are a frequent limitation [10,11]. In the following sec-
tions, we focus on primary FSGS (from this point abbreviated by ‘FSGS’ 
only) and the potential responsiveness to B cell-depleting therapies. In 
contrast to MCD, FSGS is generally a progressive disease with a ten-
dency to develop ESKD. The strongest predictor of ESKD is resistance to 
immunosuppressive therapy and failure to achieve remission, with 5- 
and 10-year kidney survival rates averaging 65% and 30% among these 
patients, respectively [12]. Even achieving partial remission is asso-
ciated with significantly improved kidney survival rates compared to no 
Fig. 1. Pathophysiology of minimal change disease and primary focal segmental glomerusclerosis. 
MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; HLA, human leukocyte antigen; GWAS, genome-wide association studies; TH2, T helper 2; 
CD, cluster of differentiation; UCHL1, Ubiquitin Carboxyl-Terminal Hydrolase L1; Ig, immunoglobulin; IL, interleukin. 
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remission [13,14]. 
2. Pathophysiology of disease 
Historically, both terms are meant to describe two separate disease 
entities but there is an ongoing debate whether MCD and FSGS may 
represent one disease continuum with a common pathogenesis and a 
histological development from MCD to FSGS due to progressive podo-
cyte injury [15]. The underlying mechanism of MCD and FSGS is not 
fully understood. Initial podocyte injury is regarded to be crucial in the 
pathogenesis of both MCD and FSGS but several causes are being dis-
cussed that might lead to podocyte depletion [6]. As depicted in Fig. 1, 
a dysregulation of adaptive immunity appears to be central in the pa-
thogenesis of MCD and FSGS. The following section will outline dif-
ferent immunological processes involved. 
2.1. Circulating permeability factors 
There is some evidence suggesting that the presence of one or more 
circulating permeability factors that disrupt the podocyte integrity in 
primary FSGS [16,17]. The strongest clinical support for this hypothesis 
in FSGS is the high recurrence rate after kidney transplantation of about 
30%–40% of patients, which may occur within hours of transplantation 
[18]. Circulating factors such as soluble urokinase plasminogen acti-
vator receptor, cardiotrophin-like cytokine factor-1 and anti-CD40 an-
tibodies have been proposed as potential causative for FSGS but none 
have been validated and proven for their pathogenic role yet [19,20]. 
For MCD there is generally less evidence indicating the presence of 
circulating factors. Nonetheless, clinical observations made in 1974, 
such as remission induced by measles infection, occurrence of MCD in 
Hodgkin's disease and clinical response to immunosuppressive therapy, 
suggest a systemic abnormality of T cell function resulting in the se-
cretion of a circulating factor [21]. The presence of a vascular perme-
ability factor produced by lymphocytes in MCD patients was first 
described by Lagrue et al. in 1975 [17,22]. Since then various candi-
dates such as the cytokines, interleukin (IL)-8 and IL-13, circulating 
hemopexin or podocyte-secreted, hyposialated angiopoietin-like 4 have 
been identified [23–26], but existing data remains inconsistent and 
unvalidated [17]. 
2.2. Atopy and eosinophils in the nephrotic syndrome 
Involvement of T helper 2 (TH2) cell-mediated immunity in the 
pathogenesis of idiopathic NS has been suggested [27]. This hypothesis 
matches with the frequently described associations between MCD and 
atopy, as the latter disposition is well-known to be driven by TH2 cell 
responses and elevated levels of IgE, IL-4 and IL-13 [28–32]. In children 
with idiopathic NS, serum levels of IgE and IL-13 correlated with dis-
ease activity, independently of atopic co-morbidities suggesting a co- 
incidence of atopy in children with idiopathic NS rather than a causal 
linkage [31–34]. Peripheral blood eosinophils are another classical di-
agnostic marker implicated in the pathogenesis of atopic diseases but its 
role in idiopathic NS is still unclear [35]. We suggest further research 
should aim at investigating the potential link of eosinophilia with 
idiopathic NS and the impact on clinically meaningful endpoints. 
2.3. Possible contact points with rituximab – B cells and beyond 
The role of B cells in the pathogenesis of MCD and FSGS has gained 
attention, mainly due to the successful use of B cell depleting agents, as 
further discussed below. This sheds new light on pathophysiological 
processes involved in these two glomerular diseases. Recently, an IgG- 
antibody directed against Ubiquitin Carboxyl-Terminal Hydrolase L1 
(UCHL1) was shown to cause podocyte detachment and associated with 
relapses of idiopathic NS in mice [36]. In a murine model, B cells ac-
tivated locally in the kidney were able to induce glomerular injury and 
proteinuria by production of IL-4. In contrast, IL-4-deficient B cells did 
not induce proteinuria, whereas overexpression of IL-4 alone was 
Fig. 2. Possible mode of action of rituximab in patients with minimal change disease and focal segmental glomerulosclerosis. 
CD, cluster of differentiation; Treg, T-regulatory cell; iNKT, invariant natural killer T cell; TFH, T follicular helper cell; TH1/2, type 1/2 T helper cell; IL-13, interleukin 
13; SMPDL-3b, sphingomyelin phosphodiesterase acid-like 3b. 
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sufficient to cause foot process effacement and proteinuria. Increased B 
cell numbers were present in the kidneys of children with FSGS com-
pared with mesangio-capillary glomerulonephritis [37]. In kidney 
biopsies of patients with MCD, STAT6 activation (induced by IL-4) was 
increased, suggesting IL-4 exposure in these patients [38]. These ob-
servations suggest that B cells are involved in the pathogenesis of MCD 
and FSGS, possibly by production of cytokines, such as IL-4 [38]. In-
terestingly, IL-4 is the critical cytokine contributing to the risk of atopy 
and allergic diseases, triggering Ig class-switch to produce IgE and T 
cells to CD4+ TH2 cells [39]. Recently, Shimada et al. postulated a 
“two-hit” theory to describe the pathogenesis of MCD. Accordingly, 
cytokines (e.g. IL-13), microbial products or allergens induce a direct 
stimulation of podocytes leading to the induction of CD80 (also named 
B7.1) as the initial hit. This causes an alteration of the podocyte 
structure and increases permeability. Under normal conditions, CD80 
expression on podocytes is controlled by T regulatory (Treg) cytokines 
or production of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and IL-10 
by the podocyte itself. Hence, a second hit due to Treg dysregulation or 
impaired podocyte autoregulation is crucial and leads to sustained 
podocyte injury and MCD [40]. Modifications of T cell subsets were 
observed in patients enrolled in a multicenter, double-blind, and ran-
domized trial assessing the efficacy of rituximab compared to a control 
group in childhood MCD. A decrease of CD4+CD25highFoxP3high Treg 
cells was associated with disease relapses, while rituximab-treated pa-
tients had a low relapse rate accompanied by a low frequency of CD4 
CD8 double negative (CD3+CD4−CD8−) invariant natural killer T 
(iNKT) cells expressing an invariant T cell receptor α-chain (Vα24). 
Rituximab was shown to specifically reduce the frequency of CD4+ 
follicular T cells (TFH cells) that drive naïve and memory B cells to 
differentiate into antibody-secreting cells (see Fig. 1). As relapses are 
associated with rapid reconstitution of switched memory B cells, the 
authors conclude that B cell depletion might induce qualitative al-
terations of TFH cells and thus inhibit reconstitution of switched 
memory B cells [41]. Recently, genome-wide association studies iden-
tified different HLA and non-HLA risk loci involved in adaptive im-
munity for childhood-onset steroid-sensitive NS, supporting the concept 
of an underlying immune dysregulation in the disease pathogenesis 
[42–44]. 
2.4. A hypothetical mode of action of rituximab in MCD and FSGS 
B cells are involved in the pathogenesis of primary MCD and FSGS 
as illustrated in Fig. 2, and presumably, play more an indirect role, 
either through production of a circulating factor as proposed mainly for 
FSGS or by interaction with T cells as described in MCD. 
Rituximab, a chimeric, monoclonal IgG1 antibody, exerts its B cell- 
depleting effects via binding to CD20. Besides direct, cytotoxic effects 
(complement- and antibody-dependent), a diversity of indirect effects, 
including lipid raft modifications, kinase and caspase activation and 
effects on apoptotic/antiapoptotic molecules appear to play a crucial 
role for the observed variability in response to rituximab treatment 
[45]. In addition, other B cell-independent mechanisms might be re-
sponsible for the antiproteinuric effects of rituximab seen in patients 
with renal disease. Besides modifying effects on T cell subsets, RTX 
might also lead to a depletion of a small number of T cells that co- 
express both CD3 and CD20 (approximately 3%–5% of all circulating T 
cells), as reported in patients with multiple sclerosis [46]. A direct 
regulation of podocyte function has been postulated and sphingomyelin 
phosphodiesterase acid-like 3b (SMPDL-3b) proposed as such target 
[47]. Notably, while binding of rituximab to SMPDL-3b was shown in 
previous studies using fixed sample assays, Kim et al. could not re-
produce this in an experimental in vivo setting with nonfixed cells [38]. 
In patients at high risk for recurrent FSGS after kidney transplantation, 
rituximab treatment was associated with a lower frequency of post- 
transplant nephrotic range proteinuria compared to historical controls. 
Additionally, rituximab partially prevented SMPDL-3b downregulation 
observed in podocytes treated with sera of patients with recurrent FSGS 
after transplantation [48]. In contrast, a benefit in preventing disease 
recurrence after transplantation was not confirmed in an observational 
study [49]. Krüppel-like factor 15, a zinc-finger transcription factor 
expressed in human podocytes, contributes to mediate the beneficial 
effects of glucocorticoid therapy via stabilization of the actin cytoske-
leton of podocytes in both MCD and FSGS [50]. To date, the relevance 
of this finding in the discussion of rituximab efficacy is unclear. 
3. Immunosuppression in MCD and FSGS 
Existing treatment strategies are generally supported by a weak 
level of evidence as reflected in the current KDIGO Clinical Practice 
Guidelines for Glomerulonephritis 2012. Evidence is particularly scarce 
for adult MCD and FSGS, as most available data is derived from clinical 
trials in children and from observational studies. Supportive measures, 
such as antihypertensive, antiproteinuric and dietary approaches, are 
pivotal for all patients with proteinuric glomerular diseases [2]. MCD 
and FSGS generally show poor response to these measures, thus initial 
immunosuppressive therapy with corticosteroids is recommended for 
all patients with clinical features of nephrotic syndrome (evidence 
grade 1C) [12,51]. Current definitions for NS, complete (CR) and par-
tial remission (PR) and corresponding disease courses are given in  
Table 1. 
Initial response rates to oral glucocorticoid therapy with achieve-
ment of CR or PR in up to 75% of adult patients with MCD [4] and 
remission rates of 40% to 65% in FSGS are reasonable [54,55]. How-
ever, complicated disease courses due to i) steroid resistance (SR) (up to 
27% in MCD [4], 40%–60% in FSGS [55,56]), ii) relapses after steroid 
tapering or withdrawal (65%–80% in MCD [5], 30%–70% in FSGS 
[57]) and iii) frequently relapsing (FR) disease (10%–30% in MCD [5]) 
are common. Of note, there is an ongoing discussion whether SR exists 
in MCD or if these patients rather have unsampled FSGS due to the focal 
nature of the disease [15]. In FSGS, a prolonged initial steroid 
therapy > 16 weeks appears to be crucial to achieve CR (15% for 
steroids < 16 weeks versus 61% for steroids > 16 weeks) [58]. 
Table 1 
Definitions of nephrotic syndrome in adult patients [12,52,53].    
Steroid-dependent (SD) Two relapses during or within 2 weeks of completing steroid therapy 
Steroid-resistant (SR) Persistence of proteinuria despite prednisone 1 mg/kg/d or 2 mg/kg every other day for  > 4 months 
Frequently relapsing (FR) Two or more relapses within 6 months or four or more relapses within 1 year of achieving remission 
Complete remission (CR) Reduction of proteinuria to  < 0.3 g/d or  <  300 mg/g (< 30 mg/mmol) urine creatinine and normal serum creatinine and serum albumin   
> 3.5 g/dl (35 g/L) 
Partial remission (PR)* Reduction of proteinuria to 0.3–3.5 g/d (300–3500 mg/g [30–350 mg/mmol]) urine creatinine and stable serum creatinine (change in creatinine   
< 25%) or 
Reduction of proteinuria to 0.3–3.5 g/d (300–3500 mg/g [30–350 mg/mmol]) urine creatinine and a decrease  > 50% from baseline, and stable 
serum creatinine (change in creatinine  < 25%) 
*not seen in minimal change disease 
Nephrotic syndrome (NS) Heavy proteinuria  > 3.0–3.5 g/d or  >  3.0 g/g urine creatinine, peripheral edema and hypoalbuminemia  < 2.5–3.5 g/dL (varying definitions in the 
literature) 
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Considering the toxicity of such high steroid doses, such re-
commendations are still controversial [59]. Conversely, a short-term 
(2 months) steroid regimen may be an effective treatment option for 
adult steroid-sensitive MCD patients [60]. 
Calcineurin inhibitors (CNI), alkylating agents and antimetabolites 
are commonly used steroid sparing agents in MCD and FSGS. 
Tacrolimus monotherapy [61] or in combination with low-dose steroids 
[62] may be an option to a conventional glucocorticoid regimen as 
initial therapy for adult MCD. Nonetheless, these alternative agents are 
so far only recommended as second- or third-line agents in adults with 
FR or SD MCD and FSGS [12,51,59]. 
Cyclophosphamide, cyclosporine alone or cyclosporin in a steroid- 
combined regimen have all shown efficacy as first-line therapy in adult 
patients with SD or FR MCD [63–65]. In a Chinese study including adult 
patients with SR/SD MCD, tacrolimus was equally effective compared 
with cyclophosphamide in inducing and maintaining remission and 
might induce remission more rapidly than intravenous pulse cyclo-
phosphamide [66,67]. Whereas CNIs block T cell activation and stabi-
lize actin directly in podocytes, mycophenolate mofetil has an anti-
proliferative effect on both B and T cells. In a retrospective review of 
adult MCD cases by Waldman et al., mycophenolate mofetil was studied 
as second-line agent in 14 patients (7 SD, 4 SR, 3 partial steroid re-
sponders) showing remission in 64% of patients (6/7 SD, 1/4 SR) [4]. A 
recent multicenter clinical trial found no superiority of a low-dose oral 
steroid therapy plus mycophenolate mofetil compared with a conven-
tional oral steroid therapy alone after 4 weeks of treatment, at least for 
the first episode of MCD [68]. 
In FSGS, one randomized controlled trial (RCT) showed that cy-
closporin in combination with low-dose prednisone is superior to pre-
dnisone alone in preserving renal function and achieving CR or PR [69]. 
However, the active treatment period with cyclosporin was only six 
months in this study and relapses were common after remission, oc-
curring in 60% of remitters by week 78 [69]. Another five-year follow- 
up study showed higher remission rates of cyclosporin with pre-
dnisolone (85.7%) compared to azathioprine with prednisolone (80%) 
and prednisolone alone (62.5%) [54]. Tacrolimus monotherapy might 
be another option as first-line therapy for adult FSGS [70]. The efficacy 
of mycophenolate mofetil alone compared to steroids has never been 
tested. One RCT compared a 12-months course of cyclosporin to a 
combination of oral pulse dexamethasone and mycophenolate mofetil 
in 93 children and 45 young adults with SR FSGS and used six primary 
outcome levels of proteinuria response. No difference was seen in 
achieving PR or CR in the first year (primary outcome) in both, adults 
and children. Nevertheless, good outcome levels (level one to three) 
were achieved in 45.9% of cyclosporin treated and 33.3% in the com-
bined dexamethasone/ mycophenolate mofetil group. Additionally, 
there was no significant difference in maintaining remission for 
26 weeks after cessation of treatment (main secondary outcome) among 
the two subgroups [71]. As the study was underpowered and secondary 
forms of FSGS were likely included, results may be interpreted cau-
tiously [72]. One open label randomized pilot study from India com-
pared the efficacy (measured end point was change in urinary protein/ 
creatinine ratio) of mycophenolate mofetil in combination with pre-
dnisolone to prednisolone alone. After 6-months, the mycophenolate 
mofetil-based regimen was as effective as steroids alone but remission 
was induced faster and steroid exposure could be reduced [73]. Addi-
tional treatment with chlorambucil in combination with steroids 
showed a lack of efficacy in a RCT [74]. In complicated disease courses, 
including SD, SR or FR FSGS, the same agents have been evaluated in a 
few randomized and observational studies [55]. One RCT compared 
tacrolimus and cyclophosphamide, both in combination with pre-
dnisone, in adult patients with SR or SD FSGS and showed similar ef-
ficacy of both regimens. Six- and twelve-month remission rates were 
67% and 73% in the tacrolimus-group, compared with 56% and 67% in 
the cyclophosphamide-group [75]. Other immunosuppressive agents 
have been tested in small trials or case series such as levamisole, 
mizoribine, tumor necrosis factor-α inhibitors, pirfenidone, fresoli-
mumab, saquinivir and sirolimus [6] and the results have been re-
viewed elsewhere [57]. 
Each of the described steroid sparing agents has major dis-
advantages. CNI and antimetabolites show frequent relapse rates after 
withdrawal in both MCD and FSGS [76]. CNI lead to nephrotoxicity 
with prolonged use and serum levels need to be monitored tightly 
whereas mycophenolate mofetil has dose-dependent effects on the 
gastrointestinal system and bone marrow [3]. Alkylating drugs like 
cyclophosphamide are very efficient but have major toxic side effects 
including infertility, urotoxicity and oncogenicity [77]. Neoplastic 
complications of alkylating drugs may occur years or even decades after 
treatment exposure [78]. Thus, most trials may have underestimated 
the true number of malignancies attributable to the treatment and thus 
the malignancy risk of these agents. In view of the availability of 
modern, effective and well tolerated drugs these limitations argue for 
alternatives in the management of MCD and FSGS. 
4. Rituximab 
Rituximab is approved for the treatment of non-Hodgkin's lym-
phoma, rheumatoid arthritis (RA) and ANCA-associated vasculitis 
(AAV) by the U.S. Food and Drug Administration (FDA) and European 
Medicines Agency (EMA). Beyond that, rituximab is increasingly used 
off-label in various autoimmune diseases, including myasthenia gravis, 
systemic lupus erythematosus, idiopathic thrombocytopenic purpura 
and Sjögren syndrome [79]. 
4.1. Safety 
In these indications, rituximab showed a favorable long-term safety 
profile [80]. Infusion-related reactions are frequent, manifesting as an 
immediate hypersensitivity reaction. A pooled analysis of patients with 
RA reported infusion-related reactions in about 25% of patients during 
the first infusion with less than 1% of cases considered as serious [81]. 
Thus, pretreatment with paracetamol, antihistamines and corticoster-
oids is recommended [80]. Hepatitis B virus (HBV) reactivation in 
HBsAg-negative/ HBcAb-positive patients following rituximab has been 
reported and can be prevented by HBV-screening and antiviral pro-
phylaxis [80]. Severe infectious complications, such as Pneumocystis 
jirovecii pneumonia (PCP) and progressive multifocal leukencephalo-
pathy (PML) due to reactivation of JC virus are rare but potentially fatal 
complications, mainly described among patients with lymphoproli-
ferative disorders and concomitant or previous exposure to other im-
munosuppressive agents [80,82]. To our knowledge, no case of PML has 
been reported in patients treated with rituximab monotherapy. Given 
the fact that rituximab treatment often allows tapering or withdrawal of 
other immunosuppressants, the true risk of severe infections attribu-
table to rituximab is unclear [83]. Infectious complications are typically 
reported in patients with pre-existing immune defects, significant co- 
morbidities or concomitant intense immunosuppression [84]. Among 
patients with RA, the overall serious infection rate was 4.31 per 100 
patient-years [81]. A slightly higher risk was found among 370 patients 
with various autoimmune diseases, with a rate of serious infections of 
5.3 per 100 patient-years during rituximab therapy [85]. Importantly, 
infection rates vary between indications, an observation that may be at 
least partly explained by different steroid-regimes. A higher infection 
rate is seen in patients with AAV, as shown in the landmark trials RAVE 
and RITUXVAS [86–88]. In RITUXVAS, 21.2 serious infections per 100 
patient-years were seen [87]. Reported rates in observational studies 
are even higher and trimethoprim-sulfamethoxazole prophylaxis should 
be considered in these patients [89,90]. In contrast, low infection rates 
are reported in patients with NS. In a retrospective analysis of 24 adult 
patients who received rituximab for membranous nephropathy 
(n = 11), MCD (n = 7), FSGS (n = 4) and membranoproliferative 
glomerulonephritis (n = 2) only one single serious infection (1.6 per 
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100 patient-years) was reported (bronchopneumonia), but fully re-
covered after a course of antibiotics [91]. NEMO, a prospective off-on 
trial, evaluated the effects of rituximab in 10 children and 20 adults 
with MCD, mesangial proliferative glomerulonephritis and FSGS. After 
one year of follow-up 5 serious infections were observed in the adult 
subgroup (25 per 100 patient-years). At the time of infection, all pa-
tients were still receiving concomitant immunosuppressive treatment 
and all fully recovered [92]. In contrast, no serious infectious compli-
cations were observed in a number of studies [93–98]. Non-uniform 
reporting of serious infectious complications may explain these differ-
ences and information from RCTs are expected to inform about the true 
infectious risk of rituximab in these diseases. A detailed overview of 
infectious complications is provided in supplementary Table 1 (see 
supplementary appendix). 
Hypogammaglobulinemia and late-onset neutropenia are two other 
side effects associated with rituximab [80]. Patients with nephrotic 
syndrome might be at particular risk for persistent hypogammaglobu-
linemia and, in children, low IgG levels at baseline appear to increase 
the risk [99,100]. Thus, monitoring levels of immunoglobulins after 
rituximab application may be informative, especially in patients with 
recurrent infections, to identify the actual risk of hypogammaglobuli-
nemia in these patients and potentially predict the infection risk. 
Long-term data evaluating the malignancy risk after rituximab in 
renal disease is scarce. A retrospective study analyzing the malignancy 
risk of 323 patients with AAV over a mean follow-up of 5.6 years 
showed that rituximab-treated patients had a lower malignancy risk 
than cyclophosphamide-treated patients. Notably, rituximab was not 
associated with an increased malignancy risk in patients with AAV 
compared with the general population [101]. In the above-mentioned 
safety-study by van den Brand et al., three blood malignancies and five 
solid cancers (two of them fatal) were observed and possibly related to 
the combined therapy of an alkylating agent (cyclophosphamide or 
chlorambucil) with corticosteroids during a period of 40 months follow- 
up of patients with membranous nephropathy. In comparison, 2 solid 
cancers were observed in the rituximab-group and assessed as unrelated 
to treatment by physicians directly in charge of the patients [102]. 
Corresponding long-term follow-up data for rituximab in MCD and 
FSGS is not available. To address this appropriately, studies with a 
follow-up period of 60 months or longer are needed. 
4.2. Dosing 
4.2.1. Initial dosing 
The optimal initial dosing of rituximab for off-label indications re-
mains unknown. A classic four-dose protocol consisting of 4 weekly 
doses of 375 mg/m2 of body surface area is used for hematologic in-
dications, whereas a regimen of 2 applications of 1 g fixed-dose two 
weeks apart is used in RA. For adults with MCD or FSGS the optimal 
initial dosing remains unknown. Different dosing protocols (375 mg/m2 
of one to four weekly doses or 1 g once or on day 1 and 15) were used in 
subgroups of a few retrospective studies [93–95,97,103,104] and 3 
prospective trials [92,96,105]. Here, either no correlation was found 
between the different treatment protocols [93,94] or no conclusions 
could be made because of the small size of the treated subgroups [95]. 
There is some evidence that even a single-dose of rituximab (375 mg/ 
m2) may be effective to induce remission and reduce relapse rates in 
adult MCD and FSGS [92,105]. Larger, controlled trials are urgently 
needed to allow comparisons between different dosing protocols in 
MCD and FSGS. 
4.2.2. Subsequent dosing 
Rituximab usually persists in the circulation for 3 to 6 months, 
followed by recovery of B cells to pretreatment levels by 12 months 
[106]. In patients with nephrotic range proteinuria however, drug half- 
life is shortened due to urinary loss of rituximab [80]. Correspondingly, 
lower rituximab levels were reported in proteinuric patients with 
membranous nephropathy compared to non-proteinuric patients with 
RA who received the same dosing regimen [107]. Hence, a shorter half- 
life of rituximab among patients with NS may require respective 
adaptions in rituximab-dosing [108]. In MCD and FSGS, the optimal 
Fig. 3. Proposed algorithm for the application of rituximab in minimal change disease. 
MCD, minimal change disease; CI, contraindication; DM, diabetes mellitus; CR, complete remission; SR, steroid-resistance; Dx, diagnosis; FSGS, focal segmental 
glomerulosclerosis; FR, frequently relapsing, SD, steroid-dependent; PR, partial remission; CPA, cyclophosphamide; CNI, calcineurin inhibitors; CSA, cyclosporin A; 
TAC, tacrolimus; MMF, mycophenolate mofetil; CD, cluster of differentiation; RTX, rituximab. 
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timing and dosing of rituximab-reapplication to either maintain re-
mission or in disease relapse are not known. After B cell depletion, re- 
emergence begins with CD19+ transitional B cells, thus measuring 
CD19+ B cells was proposed for monitoring rituximab-treatment in RA 
[109]. Another rationale supporting CD19-monitoring was a masking- 
effect of CD20 antigen upon rituximab-binding. However, this could not 
be confirmed ultimately [110] and additional evidence exists that ri-
tuximab might interfere with CD19 expression as well [111]. Although 
B cell reconstitution after rituximab is associated with a certain risk for 
disease recurrence, remission may last despite complete B cell recovery 
and relapses can occur in the presence of sustained depletion of B cells 
[112–115]. Hence, B cell recovery after rituximab appears to be an 
unreliable marker to predict relapses in patients with NS [116]. De-
layed reconstitution of switched memory B cells may be useful to pre-
dict relapses in those patients [116]. Additionally, an increase in the 
CD4+/CD8+ T cell ratio after rituximab was observed but no associa-
tion with the individual relapse risk could be drawn [116]. 
Currently, no guideline exists for the use of rituximab in MCD and 
FSGS. A possible treatment algorithm how and when rituximab may be 
applied in these entities is provided in Fig. 3 for MCD and Fig. 4 for 
FSGS. 
4.3. Efficacy 
Treatment with rituximab, despite the paucity of efficacy data, 
changed the therapeutic landscape in both diseases. While reduction/ 
withdrawal of steroids and concomitant immunosuppression was pos-
sible in most cases, relapse rates remained low and were significantly 
reduced compared to time periods before rituximab administration. 
Retrospective studies with long term follow-up provided evidence that 
relapse free survival can be achieved in the long run, which argues for 
an immunologic switch at least in some patients. Table 2 provides an 
overview of trials investigating the efficacy and safety of rituximab in 
MCD and FSGS. Respective RCTs for this indication are limited to pe-
diatric studies. 
Less evidence supports the use of rituximab in adult patients with 
MCD or FSGS. A long-term follow-up of 16 adult patients with SD/SR/ 
FR MCD treated with rituximab together with steroids showed CR in 13 
patients enabling discontinuation or tapering of steroids. At a median 
follow-up of 44 months, 8 patients remained in remission and relapses 
occurred in 7 patients with re-application of rituximab in 4 of these, 
while one patient had no response to therapy [103]. In another retro-
spective analysis of 17 adult patients with SD/FR MCD, rituximab 
treatment led to a significant reduction of relapses per year (1.32 +/− 
0.85 to 0.16 +/− 0.21, p  <  0.05) and tapering of concomitant steroid 
therapy [93]. In this study, relapse rates were lower in patients who 
received rituximab in remission compared to those not in remission 
(20% and 57%, respectively). In NEMO, total relapses decreased from 
88 to 22 during one year of follow-up, compared with the year before 
RTX application. The steroid maintenance dose per patient decreased 
from a median of 0.27 mg/kg to 0 mg/kg (p  <  0.001). The effects were 
significant across all subgroups (children, adults, MCD and FSGS) [92]. 
A retrospective study of the Spanish GLOSEN registry compared 50 
adult patients with SD/FR NS treated with steroids rituximab in com-
bination with another immunosuppressant. While 28 patients received 
additional rituximab treatment, 22 patients served as control group. CR 
was achieved in 82% in the rituximab group versus 63% in the control 
group. The relapse rate per year before and after rituximab application 
was significantly reduced (p  <  0.001) and additional im-
munosuppressants to achieve sustained remission were lower in the 
rituximab group than in the control group. The baseline relapse rate 
before rituximab treatment was significantly higher in the rituximab 
group than in the control group, thus a direct comparison between the 
groups was not possible [94]. Guitard et al. evaluated 41 adults with 
MCD receiving rituximab in a multicenter retrospective study. Overall 
response, defined as remission of NS and withdrawal of at least one 
immunosuppressant, was achieved in 78%. In the median follow-up 
period of 39 months, relapses occurred in 18 responders (56%). Of 
these, 17 received a second course of rituximab leading to clinical re-
sponse. 9 patients had sustained remission even after B cell recovery 
[95]. In 2014, we analyzed available study data (14 studies) of adult 
patients (n = 86) with SD/FR MCD (n = 77) or FSGS (n = 9) regarding 
relapses before and after rituximab treatment. Treatment with ritux-
imab reduced the number of relapses per year from 1.3 (0–9) before 
Fig. 4. Proposed algorithm for the application of rituximab in primary focal segmental glomerulosclerosis. 
FSGS, focal segmental glomerulosclerosis; CR, complete remission; MCD, minimal change disease; RTX, rituximab; IS, immunosuppressive; CNI, calcineurin in-
hibitors; CSA, cyclosporin A; TAC, tacrolimus; PR, partial remission; CPA, cyclophosphamide; MMF, mycophenolate mofetil; CD, cluster of differentiation. 
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rituximab to 0 (0–2) after rituximab (p  <  0.001), while proteinuria 
decreased from 2.43 (0–15) g/day to 0 (0–4.89) g/day (p  <  0.001), 
respectively [117]. Of note, the number of patients with FSGS included 
in this study was small (n = 9) and all were steroid-responsive. 
Roccatello et al. reported results of eight patients with FSGS having 
major risk factors precluding corticosteroids or conventional im-
munosuppression who received high-dose rituximab (8 weekly doses of 
375 mg/m2) and were prospectively followed up for a minimum of 
2 years. Only one patient showed an improvement of proteinuria and 
renal function while 7 patients did not respond and had persistent 
proteinuria in nephrotic range [96]. The low response rate might be 
attributed at least partially to a high number of secondary forms of 
FSGS among the cohort, as the included patients were comparably old 
with a high rate of co-morbidities and heterogenous biopsy character-
istics (only 2 out of 8 patients showed widespread podocyte foot process 
effacement). Similar negative findings were reported from the GLOSEN 
registry. Of eight patients with SR FSGS and previous failure of at least 
one additional immunosuppressant, only three showed a positive in-
fluence of rituximab [97]. In a recent retrospective multicenter study of 
older patients (≥ 60 years) receiving immunosuppressive therapy for 
MCD/FSGS, rituximab induced CR or PR in 18 out of 23 individuals 
[104]. In a recent prospective single-centre study from India, 24 pa-
tients (mean age 24.29 years, 17–48) with SD/SR MCD (n = 11) or 
FSGS (n = 13) and CNI-dependence, rituximab was used to maintain 
remission. All patients were in CR or PR at the time of rituximab -ad-
ministration. After 12 months, patients with MCD and SD NS had ex-
cellent outcomes with CR occurring in 100% and 93% respectively, 
while patients with FSGS or SR NS could maintain CR in only 38% and 
22% respectively [98]. Considering the complexity of the study popu-
lation (dependence to CS and CNI) and the study design (rituximab use 
for maintenance treatment), comparisons of these results with other 
studies are limited. It should be emphasized that several of the pre-
sented studies have significant limitations, mainly due to mixed cohorts 
of patients with MCD and FSGS or patients diagnosed as idiopathic NS 
without further differentiation. Furthermore, reported patients had 
varying previous treatment modalities and response definitions, de-
clared as SD, SR, or FR. Presumably, a proportion of patients diagnosed 
as SD/SR/FR FSGS actually exhibit an underlying secondary cause of 
disease and therefore show no response to any immunosuppressive 
agent. 
Currently, three controlled trials have been initiated independently 
in order to assess the efficacy and safety of rituximab in adult MCD and 
FSGS. TURING (EudraCT: 2018–004611-50) is a randomized, double- 
blind, placebo-controlled trial investigating safety and efficacy of ri-
tuximab in combination with steroids to steroids alone in 112 patients 
with relapsing or newly diagnosed MCD or FSGS. RIFIREINS 
(NCT03970577) is a French multicenter trial of 98 adult patients with a 
first episode of MCD comparing the efficacy of rituximab versus steroids 
to maintain remission. Lastly, a smaller open-label RCT 
(NCT03298698) will compare continued treatment with high-dose 
prednisone to treatment with rituximab in adult patients with MCD/ 
FSGS unresponsive to 8 weeks of high-dose prednisone. 
Taken together, rituximab appears to be a promising strategy for 
FR/SD MCD to reduce relapse rates and corticosteroid exposure, al-
though the evidence is still limited. The efficacy data in patients with 
FSGS are conflicting so far. 
5. Conclusion 
NS in adults due to MCD or FSGS is a heterogenous disease complex 
with a highly variable clinical course. Current treatment strategies are 
based on supportive, antiproteinuric measures and immunosuppressive 
agents such as steroids, alkylating agents and CNIs. Steroid-depen-
dence/resistance or frequent relapses require prolonged drug exposure 
resulting in high rates of adverse events attributable to these drugs 
[118]. B cells are involved in the pathogenesis of MCD and FSGS, giving 
a rationale for a targeted therapy in both entities. While efficacy and 
safety of rituximab are shown for several autoimmune-mediated dis-
eases, clinical data supporting its use in MCD and FSGS is still limited. 
Consequently, rituximab is still a second line treatment option for these 
entities, reserved for patients with a complex disease course or with 
contraindication for first-line agents. Several ongoing RCTs will hope-
fully provide evidence-based data in the upcoming years. Until then, 
several questions related to the use of rituximab in these patients re-
main unanswered [119]. Drug-safety and long-term efficacy, the op-
timal regimen for rituximab-application, prediction of relapses after 
rituximab and the role of peripheral blood eosinophils in adult MCD 
and FSGS are central issues that we aim to address with RITERM, a 
multicenter, international, retrospective study. 
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